Cancer calls for papers / meetings & conferences

Call for Abstracts: Society for Immunotherapy of Cancer 27th Annual Meeting

October 26-28, 2012 North Bethesda, Maryland

The SITC 27th Annual Meeting allows for scientific exchange of the most cutting-edge preclinical and clinical data on immunotherapies and biological therapy of cancer. The program included dynamic presentations, interactive panel discussions and scientific posters on the most timely topics in cancer immunotherapy as well as vital information on clinical trial design and regulatory issues to advance collaboration and translation of cancer immunotherapies.

SITC is ideally positioned to meet the identified needs of our attendees. SITC’s strength lies in its history of organizing successful scientific conferences that gather clinicians and scientists from around the globe to interact and discuss the most important issues in cancer immunotherapy. By addressing these needs, SITC advances effective, efficient research and interaction on promising cancer therapies with biological and immunological agents. Through its integrated programs, SITC promotes productive collaboration among scientists and with other organizations in the field. Ultimately this scientific exchange and collaborative environment will lead to better cancer patient outcomes with novel cancer immunotherapies.

The SITC 27th Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:

Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
Discussion of novel therapies and applications based on the research presented
Interactions with industry to promote access to novel agents for clinical development

Intended Audience

The audience for this program is basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.

Program Goals

Exchange information on the most recent advances in tumor immunology and cancer immunotherapy
Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment
Identify promising research opportunities, new techniques and clinical applications incorporating these advances
Establish dialogue between academia, industry and government on these advances

Expected Learner Outcomes

Upon completion of this program, the participants will be able to:

Summarize the most recent advances in tumor immunology and cancer immunotherapy
Integrate recent advances in cancer immunology and immunotherapy into basic, clinical and translational research
Incorporate new research and techniques into clinical applications for cancer immunotherapy
Establish and solidify collaborations among the various members of academia, industry, government and clinical practices to promote clinical evaluation of these advances in more efficient trials

Abstracts

Each year, SITC has an open call for abstract submission for the SITC 27th Annual Meeting.

Submitting an abstract is free to members and non-members alike, so all are encouraged to submit. By submitting an abstract, you will be eligible to present a poster during the SITC 27th Annual Meeting and will be in consideration for one of the oral abstract presentation slots available in the plenary and concurrent sessions each day of the program. In addition, should you meet the criteria, you may be eligible for a Young Investigator Travel Award and possibly in contention for the SITC Presidential Award.

The deadline to submit an abstract is July 11, 2012.

Abstract Categories

Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
Combining Immunotherapy and Other Therapies
DC Subsets / Cancer Vaccines
Immunity of Oncolytic Viruses
Immunotherapy Combinations *
Innate Immunity in Cancer *
Single Cell High Throughput Technologies Immune Monitoring
T Cell Manufacture and Potency Testing
T Cell Modulating Strategies
Targeted Therapies and Anti-Tumor Immunity *
Targeting Immune Suppression
Therapeutic Monoclonal Antibodies in Cancer *
Tumor Microenvironment *
Tumor Vasculature, Chemokines and Lymphocyte Trafficking to the Tumor *

* Denotes poster only category. Abstracts submitted in these categories will be eligible for poster presentation only. However, abstracts submitted in these categories and noted eligible for Young Investigator Awards will be considered for both poster and oral presentations.

Abstracts submission for the SITC 27th Annual Meeting runs May 7 - July 11, 2012 through the SITC website.

Call for Abstracts: 12th International Conference on Cancer-Induced Bone Disease

15 to 17 November, 2012 Lyon, France

Abstract Submission Deadline: 2 July 2012

Call for Late-Breaking Abstracts: 1 August 2012

The International Meeting on Cancer-Induced Bone Disease is among the most exciting international occasions for the exchange of the latest scientific discoveries. They are designed to allow attendees to enhance their knowledge of diseases of the skeleton, basic bone biology, mineral metabolism, and their correlation to oncology.

Discussions on the latest advances in innovative treatments and cutting-edge practices await you at the 2012 event. The conference takes place 15-17 November 2012 in Lyon, France. The world’s leading scientists and researchers will be on-hand to share their expertise in bone metastases and bone and cancer cell biology.

Learning Objectives
The importance of both the physical and cellular bone microenvironment and the hematopoietic stem cell niche in supporting the growth of metastatic cancer cells
The role of cancer stem cells and hematopoietic stem cells in the metastatic process
The current state of the field of genomics and proteomics as applied to bone metastasis
The efficacy of new therapeutic agents and imaging techniques for bone cancers and bone metastasis
The consequences of tumor cells on the skeleton
Understanding of the mechanisms of therapy resistance

IBMS and CABS meetings are premier international scientific events that provide an international forum to present and discuss current basic and clinical science in the rapidly advancing field of skeletal complications of cancer.

International Bone and Mineral Society (IBMS)
401 N Michigan Ave Chicago, Suite 2200, IL 60611 USA
Phone: +1 312-321-5113 | Fax: +1 312-673-6934 | Email: info@ibmsonline.org

Call for Abstracts: American Society of Human Genetics 62nd Annual Meeting

Tuesday, November 6 through Saturday, November 10, 2012 San Francisco, California

The receipt deadline for new abstract submission is June 4, 2012 at 8:00 pm (US EDT).

The world's top scientists and clinicians in the human genetics field will gather to present their latest research findings at the 62nd Annual Meeting of the American Society of Human Genetics (ASHG), which will be held on November 6-10, 2012, in San Francisco, CA (http://www.ashg.org/2012meeting). ASHG is the primary professional membership organization for human genetics specialists worldwide, representing nearly 8,000 researchers, academicians, clinicians, genetic counselors, nurses, and others with a special interest in this area (http://www.ashg.org).

The ASHG Annual Meeting continues to be the largest human genetics meeting in the world, attracting more than 7,000 scientific participants each year. The ASHG 2012 Meeting will provide attendees with the latest information about cutting-edge developments in human genetics and genomics research. In addition, nearly 250 U.S. and international exhibitors at this year's ASHG Exhibitor Trade Show will offer an unprecedented opportunity to view the latest advances in genetics-related products and services derived, in part, from work presented at previous ASHG meetings.

Topics to be addressed in the scientific program for the ASHG 2012 Meeting will include: gene discovery in human genetics; new insights and challenges from next generation sequencing; advances in medical genetics and translation/applications in clinical care; progress in gene therapy; personalized medicine; cancer genetics; advances in non-invasive prenatal diagnosis; revelations about human alleles from studies of model organisms; implications of population genetic studies; modeling in statistical genetics; data centralization and its implications for our field; ethical, legal and social implications of genomics; changes in genetics education; and much more.

For more information about the ASHG 2012 Annual Meeting, or to register and/or submit an abstract for presentation at this year’s meeting, please go to: http://www.ashg.org/2012meeting.

Call for Abstracts: Inducing and Breaking Tolerogenic Antigen-Presenting Cell Function

Thursday, 5 July 2012 London, United Kingdom

The Deadline for abstract submissions for oral presentation is May 30th 2012

Professional antigen-presenting cells (APC) such as dendritic cells (DC) and macrophages play a critical role in the initiation and maintenance of a T cell-mediated immune response. APC are essential for T cell priming, differentiation and activation in lymphoid tissue and at sites of inflammation. Understanding the molecular mechanisms via which APC function can be controlled may give novel insights into how T cell mediated immunity may be induced or blocked. This meeting will highlight current research aimed at inducing APC with tolerogenic function in order to treat inflammatory disease (e.g. rheumatoid arthritis) as well as work aimed at boosting the immunostimulatory function of APC in the context of cancer. The meeting will also highlight recent progress on the suppressive effects of CD4+ regulatory T cells on APC function, and how these can be overcome.

This event has CPD accreditation and will have a discussion panel session.

On registration you will be able to submit your questions to the panel that will be asked by the chair on the day of the event

Meeting chairs: Dr Leonie Taams, Senior Lecturer in Immunology, King's College London Centre for Molecular and Cellular Biology of Inflammation and Dr Catharien Hilkens, Reader in Immunotherapy, Newcastle University , UK

Email: enquiries@euroscicon.com

Web: www.euroscicon.com

For all accommodation and travel enquiries please contact accommodationandtravel@euroscicon.com

Call for Abstracts: Markers in Cancer 2012

October 11-13, 2012 Holywood, Florida

Deadline for submission: June 19, 2012, by 11:59 PM (EDT)

Abstracts must be submitted online using the official Markers in Cancer 2012 Abstract Submitter. E-mails and word processing files submitted outside this program will not be accepted. Each First Author will receive an e-mail to verify the abstract has been received.

Markers in Cancer 2012 (formerly known as the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer) will stimulate discussion on the use of biomarkers as a tool for optimizing detection and treatment in oncology.

Designed for clinicians, pathologists, clinical and translational researchers, statisticians, radiologists, and others who specialize in molecular diagnostics, the meeting will present the latest advances in cancer markers to assess drug efficacy, improve prognostic and predictive evaluations and imaging, and enhance clinical trial development.

This year's Meeting will focus on practice-oriented translational research. Join us in Florida to review and explore the latest innovations in cancer markers.

Authors must select one topic category that best fits the subject of their abstract. The Markers in Cancer Scientific Committee reserves the right to recategorize an abstract.

Clinical Evaluation of Biomarkers, including:
- Biomarker Readiness for Clinical Application
- Assay Validation
- Clinical Qualification
Imaging Biomarkers
Immune System and Immunotherapeutic Markers
Mechanism-based Markers of Resistance and Toxicity
Blood-based Markers, including:
- Circulating Tumor Cells/Cancer Stem Cells
- Plasma DNA
- Proteomics
Cell Signaling Pathways
Genetics, Genomics, Epigenetics, and Gene Expression, including:
- Bioinformatics in Biomarker Research
- Early Translation of Multi-Dimensional Markers
Regulatory Science, Policy, and Knowledge Transfer, including:
- Implementation Science
- Ethics
- IDE and Companion In Vitro Diagnostics
- Regulatory and Policy Considerations, Especially Cross-National
Other

Call for Papers: World Congress Leadership Summit on Optimizing Oncology Management

August 2-3, 2012 Boston Massachusetts

The Annual World Congress Leadership Summit on Optimizing Oncology Management provides best practices and updates to the entire oncology industry, specially focusing on the payer and how they are to handle policy and program formation.

With the influx of oncology products in manufacturer pipelines and the rising cost of treatment, it is now more imperative than ever for plans to properly contain spending while providing the best possible quality of care. As more drugs and therapies start target similar molecular pathways, competition is bound to increase. This conference will help plans evaluate the jungle of treatments out there to pin point the best coverage for their members.

New for 2012:

What new developments are in the manufacturer pipelines and how to properly prepare for them
Case Studies of oncology benefit programs that enhance member experience and quality of life
Realize cost savings by comparing and analyzing current treatments to determine efficiency
Discuss how different future models of health care delivery will affect oncology treatment access
Learn what employers are concerned about in regards to oncology benefits for their employees

Call for Papers: Submit Abstract for Presentations

The World Congress Leadership Summit on Optimizing Oncology Management is now accepting abstract submissions for 2012! Due: June 20th, 2012.

Who Can Submit

World Congress welcomes submissions from employers, providers, health plans, public purchasers, pharmaceutical companies, researchers and analysts. Presenters are encouraged to submit abstracts on current and emerging issues related to the conference theme.

Call for Abstracts: 16th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer

October 27-29, 2012 Boston, Massachusetts

Abstract submission opens May 15, 2012.

Deadline for abstract submissions is 11:59 pm ET on July 15, 2012.

The Collaborative Group of the Americas on Inherited Colorectal Cancers (CGA-ICC) invites the submission of abstracts regarding clinical, basic science, and/or psychosocial aspects of hereditary colorectal cancer. Our goal is to provide a comprehensive update on the status of research and to stimulate collaborations, recruitment of subjects, and ideas for the development of other studies. Authors may submit abstracts of completed work, work in progress, or work presented elsewhere within the past 12 months. All abstracts that are appropriately formatted and contain appropriate content will be accepted for poster or podium presentation. Therefore, meeting and hotel registration is encouraged at the time of abstract submission. To register, please go to www.ccfcme.org/cga12.

Abstract Submission Instructions: Abstracts will only be accepted electronically and should be submitted via email to abstract@cgaicc.com on or after May 15, 2012. The deadline for receipt of abstracts is 11:59 pm ET on July 15, 2012. All abstracts with appropriate content and formatting will be accepted for poster or podium presentation. Please indicate in your email if you would like your abstract considered only for poster presentation. All submitting authors will receive confirmation of their abstract submission by email.

Abstracts will be selected for podium presentation based on scientific merit. Notification of acceptance for podium and poster presentations will be acknowledged by email in August, 2012. Abstracts will be published in the December 2012 issue of the journal Familial Cancer.

Abstract Formatting Instructions: Limit abstracts to one page, typed in 12-point Times New Roman font, single-spaced with one-inch margins, and left justified. Organize the abstract into Background, Methods, Results, and Conclusions. Define all abbreviations. Include the abstract title, full names and institutional affiliations of all authors, and email address of the corresponding author at the top of the abstract. Underline the name of the presenting author. Abstracts must not contain copyrighted material unless permission has been obtained by the author. Previously published abstracts will be excluded from publication in Familial Cancer.

Any questions regarding abstract submission should be directed to admin@cgaicc.com

Call for Abstracts: 4th Annual National Coalition of Oncology Nurse Navigators Conference: Changing the Face of Cancer Care

NCONN presents the 4th Annual Changing the Face of Cancer Care Conference October 4-6, 2012 at the Gaylord Opryland Hotel Nashville, Tennessee.

The National Coalition of Oncology Nurse Navigators Changing the Face of Cancer Care Conference is designed for oncology nurses, oncology nurse navigators, clinical nurse specialists, social workers, community health care workers, patient navigators, and other experienced health care professionals dedicated to the field of oncology. The two-day conference aims to address the real time needs of the oncology nurse navigator and/or health care professional developing or expanding a disease specific or multi-disciplinary navigation program. Attendees will be provided a wide variety of topics affecting oncology nurse navigators and their programs today. The 2012 program will delve into the genetic and genomic science and the navigation needs of melanoma, gynecological, GI, thoracic, breast, hematologic oncologic cancers. Management of disease, treatment options, side effects, program management and quality of life across the cancer care continuum will also be addressed. There is an increasing focus on providing multidisciplinary care for patients with complex diseases by integrated teams of professionals representing the relevant treatment modalities. At the 4th Annual NCONN Changing the Face of Cancer Care Conference, experts in oncology nurse navigation will provide insight into the optimal multidisciplinary management of patients with all types of cancer and its application to practice.

The National Coalition of Oncology Nurse Navigators is accepting abstracts for poster presentations at the 4th Annual NCONN Conference: Changing the Face of Cancer Care. The deadline for submission is August 1, 2012.

Call for Abstracts: Academy of Oncology Nurse Navigators Third Annual Navigation and Survivorship Conference

September 14-16, 2012 Phoenix, Arizona

Submit an abstract for AONN’s Third Annual Navigation and Survivorship Conference. This is an opportunity to share research, programs, and results with your navigation and survivorship care colleagues. This session will facilitate communication among the various professionals and programs to advance the knowledge of all our members and those in attendance.

There are several categories of abstracts, so please choose the category that best fits your abstract.

To Participate
Submit your abstract to AONN online at www.AONNonline.org/conference/abstracts or e-mail them to Conference@AONNonline.org by the due date, Friday, July 13, 2012.

Abstract/Poster Categories

Category I: Patient Education
Category II: Psychological Support
Category III: Tracking Processes Across the Continuum of Care
Category IV: Original Research
Category V: Screening Programs for the Underserved
Category VI: Community Outreach
 

Call for Abstracts: 24th Annual Fanconi Anemia Research Fund Scientific Symposium

September 27 – 30, 2012 Denver, Colorado

Session topics may include:

Bone marrow failure and transplantation
Gene therapy and stem cell expansion
Functions of FA proteins
Role of environmental and endogenous mutagens
Small molecule development and therapeutics
Other experimental therapies
Squamous cell carcinoma and HPV
Other cancers in FA
Molecular pathogenesis and control of hematopoietic and epithelial neoplasms
Pathophysiology and treatment of endocrinopathies

Abstracts may be submitted from May 29 to June 28, 2012 at www.fanconi.org. The submission site will open at 9:00 am Pacific Time on May 29 and close at 9:00 am Pacific Time on June 28. The Fund’s abstract review committee will select abstracts for oral and poster presentations based on scientific merit. Please see complete abstract submission guidelines.

Note: There will be no late-breaking abstracts submission period.

Attendance: Presenters are expected to attend for the duration of the symposium, including the closing Symposium Town Hall: An Interactive Discussion about FA Research on September 30.